Clinical trials: Heparin
Venous Thromboembolism
Dalteparin vs Unfractionated Heparin For The Prevention Of Venous Thromboembolism (VTE) In Hospitalized Acutely Ill Medical Patients
The purpose of this study is to compare the efficacy and safety of dalteparin vs unfractionated heparin for the prevention of VTE (Venous Thromboembolism) in hospitalized acutely ill medical patients.
- Trial name
- NCT00445328
- Testing
- Dalteparin (Fragmin), Unfractionated heparin
- Where
- 7 sites in India
- Volunteers
- 84 people
- Sponsor
- Pfizer
Coronary Artery Disease
Evaluation of Sirolimus-Eluting, Heparin-Coated CoCr Stent in the Treatment of de Novo Coronary Artery Lesions in Small Vessels(EVOLUTION)
The objective of this study is to assess the performance and safety of a sirolimus-eluting, heparin-coated, cobalt chromium balloon-expandable stent (Small Vessel Stent) in patients with de novo native coronary artery lesions in…
- Trial name
- NCT00233779
- Testing
- SIROLIMUS-ELUTING, HEPARIN-COATED CoCr BALLOON-EXPANDABLE STENT
- Where
- Brazil
- Volunteers
- 52 people
- Sponsor
- Cordis US Corp.
Spinal Cord Injury
Safety and Efficacy of SC0806 (Fibroblast Growth Factor 1 and a Device) in Traumatic Spinal Cord Injury Subjects
This is an open, randomized, rehabilitation-controlled study in subjects with complete Traumatic Spinal Cord Injury, where the active treatment consists of a surgical implantation of SC0806 (a biodegradable device with…
- Trial name
- NCT02490501
- Testing
- SC0806 and rehabilitation, Rehabilitation only
- Where
- Sweden
- Volunteers
- 10 people
- Sponsor
- BioArctic AB
Venous Thromboembolism
Prescription and Utilization of Low Molecular Weight Heparin in Usual Medical Practice for the Curative Treatment of Venous Thromboembolism in Patients With Cancer
The study purpose is to document the prescription and the use of Low Molecular Weight Heparin in usual medical practice in patients with cancer and established Venous Thromboembolism.
- Trial name
- NCT01803022
- Where
- France
- Volunteers
- 419 people
- Sponsor
- LEO Pharma
Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee
Dimolegin® (60 mg) Given Once Daily in Patients Undergoing Total Hip or Knee Replacement Compared to Enoxaparin
This clinical study aims to evaluate the efficacy and safety of the anticoagulant Dimolegin® compared to low molecular weight heparin (Clexane®) for the prevention of venous thromboembolic events (VTE) in patients undergoing…
- Conditions
- Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee, Venous Thromboembolism (VTE), Prevention
- Trial name
- NCT07124819
- Testing
- Sodium enoxaparin, Dimolegin
- Where
- 8 sites in Russia
- Volunteers
- 215 people
- Sponsor
- Avexima Diol LLC
Renal Failure Chronic Requiring Hemodialysis
A Pilot Study of a Heparin Dosing Algorithm for Hemodialysis
During hemodialysis treatments, patients receive heparin to prevent clotting. The purpose of this pilot study is to determine if the amount of heparin administered during a patient's hemodialysis can be individualized using an…
- Trial name
- NCT01181544
- Testing
- Heparin dose titration
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Vantive Health LLC
Deep Vein Thrombosis
Efficacy of Bemiparin Versus Enoxaparin in the Treatment of DVT
Deep-vein thrombosis (DVT) is a common but under-diagnosed medical condition that occurs when a thrombus forms in one of the large veins, usually in the lower limbs, leading to either partial or complete blocked circulation.
- Trial name
- NCT01880216
- Testing
- Bemiparin sodium, Enoxaparin sodium
- Where
- 25 sites in Georgia, Russia
- Volunteers
- 312 people
- Sponsor
- Berlin-Chemie AG Menarini Group
Peripheral Arterial Disease
Evaluation of the GORE TIGRIS Vascular Stent
The primary objective of the randomized study is to evaluate the safety and effectiveness of the TIGRIS Vascular Stent in the treatment of de novo and restenotic atherosclerotic lesions, ≤ 24cm in length, in the superficial…
- Trial name
- TIGRIS (NCT01576055)
- Testing
- TIGRIS Vascular Stent, BARD LifeStent
- Where
- 34 sites in United States
- Volunteers
- 267 people
- Sponsor
- W.L.Gore & Associates
Anticoagulant
Evaluation of the Pharmacodynamics of a Heparin With Its Biological Comparator, Subcutaneous Administration
Experimental Drug: Porcine sodium heparin, injectable solution - 5,000 IU/ 0.25 mL; Blau Farmacêutica S/A. Comparator Drug: Heparin Sodium Injection, USP, injectable solution - 5,000 IU/ 0.5 mL; Fresenius Kabi Lake Zurich.
- Trial name
- NCT05788913
- Testing
- Heparin
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Blau Farmaceutica S.A.
Heparin
Study With Heparin Sodium in Subcutaneous Administration
The purpose of this phase I study is to know the pharmacodynamic profile in humans of the sodium heparin of porcine origin of the company União Química, building from the pharmacodynamic data generated its pharmacokinetic…
- Trial name
- NCT03113084
- Testing
- Sodium Heparin UQ subcutaneous drug administration, Sodium Heparin FK subcutaneous drug administration
- Where
- Brazil
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- União Química Farmacêutica Nacional S/A
CRBSI - Catheter Related Bloodstream Infection
Investigational Study With the BD PosiFlush™ SafeScrub on NADs
This study is an investigational study to evaluate the safety and performance of the BD PosiFlush™ SafeScrub on needleless access devices.
- Trial name
- NCT06604026
- Testing
- BD PosiFlush™ SafeScrub, BD PosiFlush™
- Where
- 2 sites in Austria
- Volunteers
- 222 people
- Sponsor
- Becton, Dickinson and Company
Coronary Disease
RIAPRE - Non-interventional Registry of Anticoagulation Treatment (BI-006-IT)
RIAPRE is a non-interventional registry to be settled in Italy with the purpose of collecting data on 600 cases of high risk elective percutaneous coronary intervention (PCI) patients treated with an anticoagulation regime…
- Trial name
- NCT00317343
- Testing
- Bivalirudin (thrombin specific anticoagulant)
- Sponsor
- Nycomed
Catheter-Associated Infections, Catheter-Related Infections
Safety and Effectiveness of Novel Nitroglycerin Based Catheter Lock Solution
The objective of this Phase I/II pilot study is to evaluate the safety and effectiveness of a non- antibiotic chelator based lock solution that contains nitroglycerin in combination with sodium citrate and ethanol (NiCE lock…
- Trial name
- NCT02577718
- Testing
- Nitroglycerin-citrate-ethanol (NiCE)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Novel Anti-Infective Technologies, LLC
Acute Ischemic Stroke
PREVAIL: PREvention of VTE After Acute Ischemic Stroke With LMWH Enoxaparin ( - VTE: Venous Thromboembolism - LMWH: Low Molecular Weight Heparin)
Primary objective: To demonstrate superiority of enoxaparin 40 mg sc qd in the prevention of VTE compared to UFH (unfractionated heparin) 5000 U sc q12 hours given for 10 ± 4 days following acute ischemic stroke.
- Trial name
- NCT00077805
- Testing
- Enoxaparin sodium
- Where
- 15 sites in United States, Australia and 13 more
- Sponsor
- Sanofi
Myocardial Infarction
Full Dose Tenecteplase (TNK-tPA) Together With Heparin Sodium, Full Dose Tenecteplase With Enoxaparin, Half Dose Tenecteplase Together With Abciximab and Heparin Sodium in Patients With Acute Myocardial Infarction (AMI)
The objective of ASSENT 3 was to evaluate the safety and efficacy of full dose tenecteplase with heparin sodium (group A), full dose tenecteplase combined with enoxaparin (group B) and half dose tenecteplase combined with…
- Trial name
- ASSENT 3 (NCT02181985)
- Testing
- Full dose TNK-tPA, Half dose TNK-tPA, Heparin
- Volunteers
- 5,989 people
- Sponsor
- Boehringer Ingelheim
Cardiac Surgery
Efficacy and Safety of Sodium Heparin in Patients
The objective of this study is verify, through a randomized, single-blind, multicentre, parallel and comparative study, the effectiveness of heparin sodium of porcine origin in patients undergoing heart surgery at that require…
- Trial name
- NCT00894959
- Testing
- Heparin sodium Blausiegel 1, Heparin sodium APP
- Where
- Brazil
- Volunteers
- 104 people
- Sponsor
- Azidus Brasil
Myocardial Infarction, Acute ST-Segment Elevation
Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment Thrombolysis in Myocardial Infarction - Study 25 (ExTRACT-TIMI25)
The primary objective of the study is to determine whether enoxaparin compared to unfractionated heparin will reduce the composite endpoint of all-cause mortality and non-fatal myocardial re-infarction within 30 days after…
- Trial name
- NCT00077792
- Testing
- Enoxaparin sodium (XRP4563)
- Where
- 48 sites in United States, Argentina and 46 more
- Volunteers
- 20,506 people
- Sponsor
- Sanofi
Myocardial Infarction
A Trial Evaluating the Efficacy and Safety of Tenecteplase Together With Unfractionated Heparin Prior to Early Percutaneous Coronary Intervention (PCI) as Compared to Standard Primary PCI in Patients With Acute Myocardial Infarction (ASSENT 4 PCI)
To show whether addition of thrombolytic treatment by a single bolus injection of tenecteplase prior to early standard PCI (percutaneous coronary intervention) will improve the clinical outcome in patients with large acute…
- Trial name
- NCT00168792
- Testing
- Tenecteplase, PCI
- Where
- 176 sites in United States, Austria and 16 more
- Volunteers
- 1,671 people
- Sponsor
- Boehringer Ingelheim
End Stage Renal Disease
A Multi-Centered, Two-Arm, Randomized Study Comparing the Effects of AAT-023 (Zuragen) Solution, and Heparin on the Incidence of Catheter Related Blood Stream Infections in Tunneled Chronic Central Venous Catheters for Dialysis
The purpose of this study is to determine if AAT-023 (Zuragen) solution is superior to Heparin in preventing Catheter Related Blood Stream Infections for End Stage Renal Disease patients.
- Trial name
- NCT00628680
- Testing
- AAT-023 solution (Zuragen), Heparin
- Where
- 22 sites in United States
- Volunteers
- 415 people
- Sponsor
- Ash Access Technology
End Stage Renal Disease
Evaluation of Anti-platelet Factor 4/Heparin Antibodies in Hemodialysis Patients
To characterize the GORE® Hybrid Vascular Graft as compared to non-heparin bonded synthetic vascular grafts in terms of the prevalence and persistence of anti-platelet factor 4 / heparin antibodies (anti-PF4 / H antibodies).
- Trial name
- NCT02165761
- Testing
- GORE® Hybrid Vascular Graft, Non-heparin bonded synthetic graft
- Where
- 4 sites in United States
- Volunteers
- 42 people
- Sponsor
- W.L.Gore & Associates